

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Organic Preparations and Procedures International

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t902189982>

N-ACETYL- α,β -DEHYDROAMINO ACID N'-METHYLAMIDES AND N',N'-DIMETHYLAMIDES

Leszek Smelka^a; Barbara Rzeszutarska^a; Malgorzata A. Broda^a; Zbigniew Kubica^a

^a Department of Organic Chemistry, University of Opole, Opole, POLAND

To cite this Article Smelka, Leszek , Rzeszutarska, Barbara , Broda, Malgorzata A. and Kubica, Zbigniew(1997) 'N-ACETYL- α,β -DEHYDROAMINO ACID N'-METHYLAMIDES AND N',N'-DIMETHYLAMIDES', *Organic Preparations and Procedures International*, 29: 6, 696 – 701

To link to this Article: DOI: 10.1080/00304949709355251

URL: <http://dx.doi.org/10.1080/00304949709355251>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

3. A. A. Gaponov, N. Ya. Bozhanova, Z. F. Solomko and G. M. Farina, *ibid.*, 1430 (1991); CA, **117**, 48512e (1992).
4. G. Roma, M. Di Braccio, M. Mazzei and A. Ermili, *Il Farmaco Ed. Sci.*, **35**, 997 (1980).
5. a) G. Roma, G. C. Grossi, M. Di Braccio, M. Ghia and F. Mattioli, *Eur. J. Med. Chem.*, **26**, 489 (1991); b) M. Di Braccio, G. Roma, G. C. Grossi, *Il Farmaco Ed. Sci.*, **47**, 77 (1992).
6. a) B. Puodziunaite, R. Janciene, Z. Talaikyte, A. S. Zaks, Yu. M. Rabotnikov and E. A. UTsachev, *Khim.-Farm. Zh.*, **19**, 1195 (1985); CA, **105**, 133861g (1986); b) R. Janciene, *Ph. D. Diss.*, Institute of Biochemistry, Vilnius, 1985.
7. D. Nardi, A. Tajana and S. Rossi, *J. Heterocycl. Chem.*, **10**, 815 (1973).
8. R. Pennini, A. Tajana and D. Nardi, *Il Farmaco Ed. Sci.*, **31**, 120 (1976).

**N-ACETYL- α,β -DEHYDROAMINO ACID N'-METHYLAMIDES
AND N',N'-DIMETHYLAMIDES[†]**


Submitted by
(02/06/97)

Leszek Smelka, Barbara Rzeszotarska*, Malgorzata A. Broda
and Zbigniew Kubica

*Department of Organic Chemistry
University of Opole
ul. Oleska 48, 45-052 Opole, POLAND*

α,β -Dehydroamino acids belong to a large group of nonstandard amino acids, which occur in a number of entities of microbial, plant and animal origin. They are a focus of enormous interest due to their applicability to peptide and protein engineering. An α,β -dehydroamino acid incorporated into a peptide chain forms the system involving three rigid groups located on atom C $^{\alpha}$: the α,β -double bond flanked by two adjacent amide bonds. As a consequence, these amino acids provide conformational constraint to the peptide backbone and restrict the orientation of the side chain β -substituent(s), and hence generate often specific peptide secondary structures (for recent reviews on α,β -dehydropeptides, see Ref. 1-3). However, relatively little effort has been directed to explore the stereoelectronic interactions of bond C $^{\alpha}$ =C $^{\beta}$ with neighboring peptide bonds.⁴ To address this question, we prepared N-acetyl- α,β -dehydroamino acid N'-methylamides and report herein the synthesis of Ac-(Z)- Δ Abu-NHMe, Ac-(Z)- Δ Leu-NHMe and Ac- Δ Val-NHMe,⁵ the new members of the unsaturated amide series, whose conformational preferences and electronic density perturbation we recently investigated.⁴ We also

describe the synthesis of the analogous unsaturated *N,N'*-dimethyl amides, useful models in this⁴ as well as other studies on the basic properties of α,β -dehydropeptides.



The title compounds were obtained by adopting Shin's methods for the generation of the $\text{C}^\alpha=\text{C}^\beta$ bond and the incorporation of α,β -dehydroamino acids into a peptide chain.⁶⁻⁸ Benzyl carbamate was condensed in the presence of *p*-toluenesulfonic acid as a catalyst, with an appropriate α -oxo acid with azeotropic removal of water.⁶ The resulting *N* ^{α} -benzyloxycarbonyl- α,β -dehydroamino acid was cyclized by treatment with SO_2Cl_2 to an α,β -dehydroamino acid *N*-carboxy anhydride,⁷ which gives in two consecutive one-pot reactions, first with acetyl chloride and then with an appropriate amine, the final product.⁸ Yields and analytical data of the compounds synthesized are summarized in Table 1. Tables 2 and 3 list ¹H and ¹³C selected chemical shifts, respectively. All the amides obtained have sharp melting points, satisfactory elemental analyses, ¹H and ¹³C NMR spectra as expected and are of 98.8-99.8% purity as determined by HPLC. Their IR characteristic is also correct.⁴

EXPERIMENTAL SECTION

Benzyl carbamate, sulfonyl chloride, acetyl chloride, methylamine and dimethylamine were purchased from Fluka and α -oxo acids were prepared by our previous procedure.⁹ Purified solvents (Polskie Odczynniki Chemiczne) were stored over drying agents. Organic solutions were dried over anhydrous Na_2SO_4 . The solvents from reaction mixtures and column chromatographic separations were removed *in vacuo* on a rotatory evaporator at bath temperatures not exceeding 30°. Reactions were monitored and preliminary checking of product homogeneity was performed on silica gel plates (DC Alufolien Kieselgel 60 No 5553 Merck) in $\text{CHCl}_3\text{-MeOH}$ (5:1). Spots were visualized with bromine-fluorescein. Mps. were determined on a Boetius heating block and are uncorrected. HPLC analyses were performed on a Beckman "System Gold" chromatograph for Methods Development consisting of a Model 126 programmable module, a Model 168 diode array detector, a Model 210A injection valve with a 5 μl loop, a PC386SX (Warnes) with "System Gold" version 5.1 software for data collection and controller function. An Alltech Alltima, C_{18} , 5 μ , 150 x 4.6 mm column and solvent systems given in Table 1 with a flow rate 1 mL/min were applied. Elemental analyses were performed on a Perkin-Elmer analyzer.

TABLE 1. Yields and Analytical Data of N-Acetyl- α,β -dehydroamino Acid N'-Methylamides and N',N'-Dimethylamides

Amide	Yield (%)	mp. (°C) Crystallization System	HPLC		Analysis (Found)		
			Purity (%)	tR (min) (A:B) ^a	C	H	N
Ac-(Z)- Δ Abu-NHMe	58	139-141 AcOEt/Hex	98.9	3.02 ^b (95:5)	53.82 (53.40)	7.75 (8.00)	17.94 (17.63)
Ac-(Z)- Δ Leu-NHMe	76	194.5-196 Sublimed	98.8	3.72 (85:15)	58.67 (58.65)	8.75 (8.90)	15.21 (15.17)
Ac- Δ Val-NHMe	46	209-211 CHCl ₃ /Hex	98.8	2.92 (90:10)	56.45 (56.28)	8.29 (8.40)	16.46 (16.55)
Ac-(Z)- Δ Abu-NMe ₂	23	123-124.5 Et ₂ O/Hex	99.8	12.60 (95:5)	55.85 ^c (55.81)	8.32 (8.44)	16.28 (16.02)
Ac-(Z)- Δ Leu-NMe ₂ ^d	71	183-185 Sublimed	98.6	11.47 (85:15)	60.58 (60.72)	9.15 (9.35)	14.13 (14.20)
Ac- Δ Val-NMe ₂	48	176-178 ^d CHCl ₃ /Hex	99.6	8.10 (90:10)	— ^e	— ^e	— ^e

a) A = 0.1% trifluoroacetic acid, B = acetonitrile; b) tR for the (*E*)-isomer = 3.32 min in the same solvent system; c) Analyzed for 0.1 H₂O in sample; d) This compound itself is known, but yield and the above analytical data are lacking¹⁵; e) Lit.¹⁶ mp. 175-176, correct analysis

TABLE 2. ¹H NMR Spectra (δ , ppm, ³J <Hz>) of N-Acetyl- α,β -Dehydroamino Acid N'-Methylamides and N',N'-Dimethylamides

Amide	CH ₃ CO	NH	CH	CH	N'H	N'CH ₃ or N'(CH ₃) ₂
1	1.94 (s,3H)	8.89 (s,1H)	6.27 (q,1H <7.5>)	1.58 (d,3H <7.5>)	7.69 (q,1H <4.7>)	2.62 (d,3H <4.7>)
2	1.92 (s,3H)	8.92 (s,1H)	6.03 (d,1H <10.1>)	2.46 (m,1H)	7.68 (q,1H <4.5>)	2.58 (d,3H <4.5>)
3	1.87 (s,3H)	8.84 (s,1H)	-	1.62 (s,3H) 1.85 (s,3H)	7.53 (q,1H <4.7>)	2.58 (d,3H <4.7>)
4	1.90 (s,3H)	9.27 (s,1H)	5.18 (q,1H <7>)	1.62 (d,3H <7.0>)	-	2.78 (bs,3H) 2.92 (bs,3H)
5^a	1.88 (s,3H)	9.32 (s,1H)	4.88 (d,1H <9.8>)	2.63 (m,1H)	-	2.76 (s,3H) 2.94 (s,3H)
6	1.85 (s,3H)	9.06 (s,1H)	-	1.58 (s,3H) 1.61 (s,3H)	-	2.80 (s,3H) 2.91 (s,3H)

a) ¹H NMR in CDCl₃ (a 6% solution) ppm, <Hz>: 0.91 (d, 6H <6.6> (CH₃)₂C), 1.92 (s, 3H, CH₃), 2.65 (m, 1H, C'H), 2.94 and 3.13 (2 bs, 6H, N(CH₃)₂), 4.95 (dd, 1H <9.8> ⁴J <0.9> C ^{β} H), 9.45 (d, 1H ⁴J <0.9> NH). There are two sets of signals in the literature ¹H NMR spectrum of this compound in CDCl₃ solution,¹⁵ ascribed to (*Z*) (major) and (*E*) (minor) conformers being in slow equilibrium. However we did not observed any change in the spectrum after 24 h standing of the measured solution of this sample.

^1H and ^{13}C NMR spectra were recorded with a Bruker Avance DRX 300 spectrometer in DMSO-d_6 with internal Me_4Si . Assignment of proton and carbon resonances was based on DEPT, ($^1\text{H}, ^1\text{H}$)-COSY and ($^1\text{H}, ^{13}\text{C}$)-COSY techniques and in the case of quaternary carbon atoms on the HMBC experiment. For *Z/E* configuration assignment, resonances C^αH , C^βH and NH compared in a series of compounds as measured in a given solvent can be of the diagnostic values.^{10,11} The respective values in DMSO-d_6 ¹² for the series of compounds below are as follows:

(<i>E</i>)-Ac-Pro-Abu-NHMe ¹³	1.85 (d, 3H <7.5>)	5.76 (q, 1H <7.5>)	9.25 (s, 1H)
(<i>Z</i>)-Ac-Pro-Abu-NHMe ¹³	1.59 (d, 3H <7.5>)	6.49 (q, 1H <7.5>)	9.06 (s, 1H)
(<i>E</i>)-Ac-Abu-NHMe ¹⁴	1.75 (d, 3H <7.5>)	5.61 (q, 1H <7.5>)	9.13 (bs, 1H)
(<i>Z</i>)-Ac-Abu-NHMe (in Table 2)	1.58 (d, 3H <7.5>)	6.27 (q, 1H <7.5>)	8.89 (s, 1H)

The long range coupling constant 4J between NH and *trans* C^βH is also diagnostic for *Z* configuration assignment, as seen in the spectra of Ac-(*Z*)-Leu-NMe₂ in CDCl_3 [a] in Table 2]. The configuration of the remaining compounds was assumed to be *Z* on the basis of derivation of all the Abu and Leu amides from (*Z*)- α,β -dehydroamino acid *N*-carboxy anhydrides.

TABLE 3. ^{13}C NMR Spectra (δ , ppm) of *N*-Acetyl- α,β -Dehydroamino Acid *N'*-Methylamides and *N',N'*-Dimethylamides

Amide	$\underline{\text{CH}}_3\text{CO}$	$\text{CH}_3\underline{\text{CO}}$	C^α	C^βH	C^γH	$\text{C}^\alpha\underline{\text{CO}}$	$\text{N}'\text{CH}_3$ or $\text{N}'(\text{CH}_3)_2$
1	22.71	168.37	131.47	126.31	12.85	164.85	25.86
2	23.57	169.87	129.23	139.40	27.13 ^a	165.84	26.86
3	22.48	168.29	125.79	133.71	20.09 20.76	165.90	25.62
4	23.02	168.72	132.30	117.11	12.77	168.66	35.42 39.51
5	22.97	168.91	129.02	129.10	26.09 ^b	168.91	34.91 39.30
6	23.05	168.55	126.17 ^c	124.31 ^c	19.56 19.94	168.13	34.71 38.32

a) $\text{CH}(\text{CH}_3)_2$: ^1H : 0.91 (d, 6H <6.6>), ^{13}C : 22.68; b) $\text{CH}(\text{CH}_3)_2$: ^1H : 0.93 (d, 6H <6.6>), ^{13}C : 22.97; c) These assignments may be reversed.

***N* $^\alpha$ -Benzyloxycarbonyl- α,β -dehydroamino Acids** were synthesized according to Ref. 6. and were of 90.0-99.8% purity, determined by HPLC. $\text{PhCH}_2\text{OCO}(\text{Z})-\Delta\text{Abu}$ contained 5% of the (*E*)-isomer as seen in ^1H NMR spectra.

α,β -Dehydroamino acid *N*-carboxy Anhydrides were obtained according to Ref. 7. (*Z*)- ΔAbuNCA on crystallization from chloroform/*n*-hexane melted at 139-141.5° (lit. mp. 136-138°). (*Z*)- ΔLeuNCA on crystallization from benzene/*n*-hexane melted at 93-95° (lit. mp. 91-92°) and was so stable that its HPLC analysis was feasible to indicate its 100% purity. ΔValNCA on crystallization from benzene melted at 150-152° (lit. mp. 145-146°).

***N*-Acetyl- α,β -dehydroamino Acid *N'*-Methylamides and *N',N'*-Dimethylamides. General Procedure.** To a vigorously stirred solution of an α,β -dehydroamino acid *N*-carboxy anhydride (0.13 g of (*Z*)- Δ AbuNCA, 0.16 g of (*Z*)- Δ LeuNCA or 0.14 g of Δ ValNCA, 1.0 mmol each) in tetrahydrofuran (5 mL), cooled to -15° , AcCl (0.08 mL, 1.1 mmol) and NEt_3 (0.15 mL, 1.1 mmol) were added. Stirring was continued at 20° for 40 min, the reaction mixture recooled to -15° and NH_2Me or NHMe_2 (2.0 mmol) in tetrahydrofuran added (0.60 mL of 3.4 M solution of the former or 0.62 mL of 3.2 M solution of the latter). Stirring was continued at 20° overnight and the solvent evaporated.

Ac-(*Z*)- Δ Abu-NHMe (**1**), *Ac*-(*Z*)- Δ Abu-NMe₂ (**4**), *Ac*-(*Z*)- Δ Leu-NHMe (**2**) and *Ac*-(*Z*)- Δ Leu-NMe₂ (**5**). The above respective postreaction residue, dissolved in ethyl acetate was applied to a silica gel column (Kieselgel 60H Merck, 20 g) equilibrated with this solvent. The column was eluted with a mixture of ethyl acetate-ethanol (5:1) and 15 mL fractions were collected. The fractions containing the amide synthesized (TLC) were evaporated and dried at 20° over P_2O_5 at 1 mm Hg. Two former amides were crystallized from solvents given in Table 1. The remainder were crystallized from methanol-chloroform (1:4)/*n*-hexane and sublimed at 1 mm Hg using a bath of temperature 125 - 145° . Yields and analytical and NMR data are collected in Tables 1-3.

Ac- Δ Val-NHMe (**3**) and *Ac*- Δ Val-NMe₂ (**6**). The respective postreaction residue dissolved in chloroform was applied to a silica gel column (Kieselgel 60H Merck, 17 g) equilibrated with this solvent. The column was eluted with chloroform and then with a mixture of chloroform-methanol (3:1). Fractions of 5 mL were collected and these containing the amide synthesized (TLC) were evaporated, dried at 20° over P_2O_5 at 1 mm Hg and crystallized. Yields and analytical and NMR data are cited in Tables 1-3.

Acknowledgement.- The work was financially supported by a grant-in-aid from the Polish State Committee for Scientific Research. This support deserves our grateful thanks.

REFERENCES

- † Part XII. For Part XI in the series, see Z. Kubica and B. Rzeszutarska, *Zesz. Nauk. Uniw. Opolskiego: Chemia*, **17**, 63 (1994); *CA*, **123**, 340852z (1995).
1. U. Schmidt, A. Lieberknecht and J. Wild, *Synthesis*, 159 (1988).
 2. G. Pietrzyński and B. Rzeszutarska, *Polish J. Chem.*, **69**, 1595 (1995); *CA*, **124**, 261627x (1996).
 3. R. Jain and V. S. Chauhan, *Biopolymers (Peptide Sci.)*, **40**, 105 (1996).
 4. M. A. Broda, B. Rzeszutarska, L. Smelka and M. Rospenk, *J. Peptide Res.*, (in press) and cited references.
 5. Abbreviations used: Δ Abu = α,β -dehydrobutyrine, Δ Leu = α,β -dehydroleucine, Δ Val = α,β -dehydrovaline, Δ NCA = α,β -dehydroamino acid *N*-carboxy anhydride, Hex = *n*-hexane, THF = tetrahydrofuran.

6. Y. Yonezawa, C. Shin, Y. Ono and J. Yoshimura, *Bull. Chem. Soc. Jpn*, **53**, 2905 (1980).
7. C. Shin, Y. Yonezawa and T. Yamada, *Chem. Pharm. Bull. Jpn*, **32**, 3934 (1984).
8. C. Shin, Y. Yonezawa and M. Ikeda, *Bull. Chem. Soc. Jpn*, **59**, 3573 (1986).
9. R. Kozłowski, Z. Kubica, B. Rzeszotarska, L. Smelka and G. Pietrzyński, *Org. Prep. Proced. Int.*, **21**, 75 (1989).
10. A. Srinivasan, K. D. Richards and R. K. Olsen, *Tetrahedron Lett.* **1976**, 891.
11. C. Shin, M. Hayakawa, T. Suzuki, A. Ohtsuka and J. Yoshimura, *Bull. Chem. Soc. Jpn*, **51**, 550 (1978).
12. G. Pietrzyński, Z. Kubica and B. Rzeszotarska, Unpublished data.
13. G. Pietrzyński, B. Rzeszotarska, E. Ciszak and M. Lisowski, *Polish J. Chem.*, **68**, 1015 (1994); *CA*, **121**, 109659q (1994) (Confirmation of the structure by X-ray crystallography).
14. M. A. Broda and B. Rzeszotarska, in "3rd Polish-Israeli Symposium on Peptides and Proteins. From Basic Chemistry to Medical Applications, Warsaw, May 1997. Abstract Book", p. 9.
15. L. El-Masdouri, A. Aubry, G. Boussard and M. Marraud, *Int. J. Peptide Protein Res.*, **40**, 482 (1992).
16. T. Beisswenger and F. Effenberger, *Chem. Ber.*, **117**, 1513 (1984).

A FACILE SYNTHESIS FOR RACEMIC AND OPTICALLY ACTIVE 1-AMINOINDANS

Submitted by
(04/23/97)

Ramy Lidor*, Eliezer Bahar, Ora Zairi, Gasan Atili and Dora Amster

Corporate Research and Development
Teva Pharmaceutical Industries Ltd.
Chemistry Department, Abic, P.O.B. 8077
Netanya 42110, ISRAEL

In the course of development work for new central nervous system drugs, we found that a key intermediate, 1-aminoindan and particularly optically active 1-aminoindan, is not readily available in commercial quantities. We therefore developed a facile synthesis suitable for both racemic and enantiomerically pure 1-aminoindans.¹ 1-Aminoindan has previously been prepared by reduction of indanone oxime either with metal,² metal-hydride³ or catalytic hydrogenation.⁴ The disadvantage of